179232-29-2 Usage
Description
Methyl 4-bromo-2-fluorobenzoate is the methyl ester derivative of 4-bromo-2-fluorobenzoic acid (B684620), characterized by its off-white powder form. It is a chemical compound with a unique structure that makes it a valuable reagent in the synthesis of specific pharmaceutical agents.
Uses
Used in Pharmaceutical Industry:
Methyl 4-bromo-2-fluorobenzoate is used as a reagent for the synthesis of aminopyridyl-based inhibitors. These inhibitors are specifically designed to target Trypanosoma cruzi CYP51, an enzyme crucial for the survival of the parasite responsible for Chagas disease. By inhibiting this enzyme, the compound contributes to the development of anti-Chagas agents, which are essential in combating this life-threatening disease.
Check Digit Verification of cas no
The CAS Registry Mumber 179232-29-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,2,3 and 2 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 179232-29:
(8*1)+(7*7)+(6*9)+(5*2)+(4*3)+(3*2)+(2*2)+(1*9)=152
152 % 10 = 2
So 179232-29-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H6BrFO2/c1-12-8(11)6-3-2-5(9)4-7(6)10/h2-4H,1H3
179232-29-2Relevant articles and documents
HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF
-
Paragraph 0652-0653, (2021/02/25)
The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.
COMPOUNDS AND METHOD OF USE
-
Paragraph 1337, (2019/09/06)
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 47; 48, (2017/11/15)
A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject.